-
1Academic Journal
المؤلفون: K. A. Turupaev, A. V. Klimov, O. A. Khalmurzaev, G. A. Arakelyan, D. D. Ladyko, S. D. Bezhanova, V. O. Vorob’eva, A. V. Smirnova, V. B. Matveev, К. А. Турупаев, А. В. Климов, О. А. Халмурзаев, Г. А. Аракелян, Д. Д. Ладыко, С. Д. Бежанова, В. О. Воробьева, А. В. Смирнова, В. Б. Матвеев
المصدر: Cancer Urology; Том 19, № 4 (2023); 119-124 ; Онкоурология; Том 19, № 4 (2023); 119-124 ; 1996-1812 ; 1726-9776
مصطلحات موضوعية: светлоклеточный почечно-клеточный рак, organ-preserving surgical treatment, tumor thrombus, synchronous bilateral kidney cancer, papillary renal cell carcinoma, clear-cell renal cell carcinoma, органосохраняющее хирургическое лечение, опухолевый венозный тромбоз, синхронный двусторонний рак почек, папиллярный почечно-клеточный рак
وصف الملف: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1688/1499; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1323; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1324; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1325; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1326; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1327; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1328; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1329; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1330; Globocan (IARC) 2020. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf.; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Zhang C., Li X., Hao H. et al. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases. BJU Int 2012; 110(11 Pt B):E481–5. DOI:10.1111/j.1464-410X.2012.11173.x; Van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52. DOI:10.1016/j.eururo.2010.12.013; Scosyrev E., Messing E.M., Sylvester R. et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65(2):372–7. DOI:10.1016/j.eururo.2013.06.044; Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163(2):442–5.; Patel S.H., Uzzo R.G., Larcher A. et al. Oncologic and functional outcomes of radical and partial nephrectomy in pt3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis. Clin Ge-nitourin Cancer 2020;18(6):e723–9. DOI:10.1016/j.clgc.2020.05.002; Kolla S.B., Ercole C., Spiess P.E. et al. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int 2010;106(10):1494–8. DOI:10.1111/j.1464-410X.2010.09293.x; Yim K., Aron M., Rha K.H. et al. Outcomes of robot-assisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus 2021;7(5):1107–14. DOI:10.1016/j.euf.2020.10.011; Woldu S.L., Barlow L.J., Patel T. et al. Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein. Urology 2010;76(3):639–42. DOI:10.1016/j.urology.2009.10.073; Marra G., Gontero P., Brattoli M. et al. Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. Urol Oncol 2018;36(7):339.e1–8. DOI:10.1016/j.urolonc.2018.04.007; Morgan T.N., Dai J.C., Kusin S. et al. Clinical outcomes of robotic assisted partial nephrectomy for pathologic T3a renal masses with venous tumor thrombus. Urology 2022;159:120–6. DOI:10.1016/j.urology.2021.06.054; Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20(23):4559–66. DOI:10.1200/JCO.2002.05.111; Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663–71. DOI:10.1002/cncr.11234; Eisen T., Frangou E., Oza B. et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol 2020;38:4064–75. DOI:10.1200/JCO.20.01800; Gross-Goupil M., Kwon T., Eto M. et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29(12):2371–8. DOI:10.1093/annonc/mdy454; Haas N.B., Manola J., Uzzo R.G. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387(10032):2008–16. DOI:10.1016/S0140-6736(16)00559-6; Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. DOI:10.1200/JCO.2017.73.5324; Staehler M., Motzer R.J., George D.J. et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 2018;29(10):2098–104. DOI:10.1093/annonc/mdy329; Powles T., Tomczak P., Park S.H. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(9):1133–44. DOI:10.1016/S1470-2045(22)00487-9; https://oncourology.abvpress.ru/oncur/article/view/1688